MYCN and neoplasm: Moreover, regorafenib was clearly established as a RET signaling inhibitor in neuroblastoma cell lines, and its tumor suppressant effect was validated in vivo in a xenograft tumor system and in the immuno-competent TH-MYCN transgenic mouse model.